.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Moodys
Novartis
QuintilesIMS
Chubb
Cipla
Mallinckrodt
Argus Health
Citi
Colorcon

Generated: June 25, 2017

DrugPatentWatch Database Preview

VENLAFAXINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Venlafaxine Hydrochloride, and what generic Venlafaxine Hydrochloride alternatives are available?

Venlafaxine Hydrochloride is a drug marketed by Dr Reddys Labs Ltd, Osmotica Pharm, Sandoz, Pliva Hrvatska Doo, Orchid Hlthcare, Prinston Inc, Sun Pharm Inds Inc, Alembic Pharms Ltd, Aurobindo Pharma Ltd, Yaopharma Co Ltd, Zydus Pharms Usa, Heritage Pharms Inc, Aurobindo Pharma, Teva, Wockhardt, Mylan, Nostrum Labs Inc, Valeant Pharms North, Sun Pharma Global, Zydus Pharms Usa Inc, Anchen Pharms, Amneal Pharms, and Torrent Pharms Llc. and is included in twenty-six NDAs. There are two patents protecting this drug.

This drug has eighty-seven patent family members in forty-four countries.

The generic ingredient in VENLAFAXINE HYDROCHLORIDE is venlafaxine hydrochloride. There are seventy drug master file entries for this compound. Seventy-three suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

Summary for Tradename: VENLAFAXINE HYDROCHLORIDE

Patents:2
Applicants:23
NDAs:26
Suppliers / Packagers: see list67
Bulk Api Vendors: see list61
Clinical Trials: see list2,382
Patent Applications: see list1,519
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VENLAFAXINE HYDROCHLORIDE at DailyMed

Pharmacology for Tradename: VENLAFAXINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET;ORAL090555-002Apr 7, 2010ABRXNoNo► Subscribe► Subscribe
Mylan
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL078789-001Jun 1, 2011ABRXNoNo► Subscribe► Subscribe
Prinston Inc
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET;ORAL090027-004Aug 4, 2010ABRXNoNo► Subscribe► Subscribe
Dr Reddys Labs Ltd
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL078421-001May 6, 2011ABRXNoNo► Subscribe► Subscribe
Mylan
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET;ORAL077166-005Jun 13, 2008ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VENLAFAXINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-001May 20, 20086,403,120► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-002May 20, 20086,419,958► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-002May 20, 20086,403,120► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-004May 20, 20086,419,958► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-003May 20, 20086,403,120► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VENLAFAXINE HYDROCHLORIDE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,274,171 Extended release formulation of venlafaxine hydrochloride► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VENLAFAXINE HYDROCHLORIDE

Country Document Number Estimated Expiration
Slovenia797991► Subscribe
Japan2001521892► Subscribe
CroatiaP20000213► Subscribe
China1090018► Subscribe
Mexico9701873► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
AstraZeneca
US Army
McKinsey
Queensland Health
McKesson
Cerilliant
Moodys
Daiichi Sankyo
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot